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A B S T R A C T
Background: Despite its proven efficacy, infliximab is often considered to be an expensive
treatment for patients with psoriatic arthritis.
Objectives: To estimate the cost-effectiveness of infliximab among patientswith active and
progressive psoriatic arthritis.
Methods: A decision analytic model was constructed to simulate disease progression in
hypothetical cohorts of patients with psoriatic arthritis receiving infliximab maintenance
treatment. The primary responsemeasurewas change inHealthAssessmentQuestionnaire
score from a baseline estimated frommixed treatment models drawn from published clin-
ical trials. Palliative care, comprising nonbiologic disease-modifying antirheumatic drugs,
was used as a comparator. The primary outcome was quality-adjusted life years. The dose
of infliximabwas estimated for a range of 60 to 80 kg per patient body weight. The costs and
outcomes were discounted at 3.5% for a period of 40 years. Uncertainty around the results
was explored with probabilistic sensitivity analysis.
Results: The mixed treatment comparison showed a significant reduction in Health Assess-
ment Questionnaire score across all patients. The tumor necrosis factor  inhibitors were sig-
nificantly superior to palliative care but comparable with one another. The incremental cost-
effectiveness ratios for etanercept, adalimumab, and infliximab relative to palliative care were
£17,327; £19,246; and£16,942 to£23,022, respectively, acrossallpatientswithpsoriaticarthritisand
£16,613; £18,170; and £15,788 to £21,736, respectively, in the subgroupwith significant psoriasis.
Conclusion: Infliximab represents a cost-effective treatment option well within the Na-
tional Institute for Health and Clinical Excellence threshold relative to palliative care. In
light of equivalent outcomeswith other tumor necrosis factor  inhibitors, its position in the
treatment pathway is likely to be governed by treatment costs.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). Published by Elsevier Inc.
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16 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 - 2 3ntroduction
soriatic arthritis is a chronic debilitating spondyloar-
hropathy characterized by inflammatory arthritis that af-
ects the joints and connective tissue and is associated with
soriasis of the skin or nails. The annual incidence of pso-
iatic arthritis ranges between 0.1 and 23.1 per 100,000, and
he prevalence is estimated to be 1.0 to 420.0 per 100,000
cross the globe [1]. The course of psoriatic arthritis can be
ariable and unpredictable, ranging from a mild and non-
estructive disease to an erosive and deforming arthritis
seen in 40% to 60% of patients with psoriatic arthritis) [2].
atients with untreated psoriatic arthritis may have persis-
ent inflammation, progressive joint damage, severe physi-
al limitations, disability, and increased mortality risk [2].
soriatic arthritis carries a significant economic burden,
ith direct annual medical costs per patient estimated to be
3162 and mean indirect costs per patient estimated to be
11075 in Germany in 2002 [3]. As with most chronic condi-
ions, the major cost drivers of direct costs in psoriatic ar-
hritis are hospitalizations and drug treatments [3,4].
The goals of psoriatic arthritis treatment are to improve
isease signs and symptoms; prevent loss of function and
isability; prevent or control joint, tendon, and entheses
nflammation and damage; and improve quality of life
5,6]. The British Society of Rheumatology guidelines rec-
mmend that biologic disease-modifying antirheumatic
rug (DMARD) therapy should be used for those patients
ith active psoriatic arthritis (3 tender joints and3 swol-
en joints) who have no response of their disease to ade-
uate treatment (6 months) with at least two nonbiologic
MARDs (e.g., methotrexate, sulfasalazine, cyclosporine, or
eflunomide) [5].
Tumor necrosis factor  (TNF-) inhibitors have been
hown to be efficacious for patients with psoriatic arthritis
ho have had treatment failure with at least two DMARDs.
nfliximab, a TNF- inhibitor, has demonstrated significant
mprovements in the proportion of subjects with achieved
nd maintained benefits in the rheumatoid and psoriatic
omponents of the disease during a 24-week period in its
wo randomized, controlled trials, Infliximab Multinational
soriatic Arthritis Controlled Trial (IMPACT) and IMPACT2
7,8]. TNF- inhibitors in general and infliximab in particu-
ar are often considered to be costly treatment alternatives,
owever, and decisionmakers often challenge their value in
reating patients with psoriatic arthritis.
This economic evaluation was performed to assess the
ost-effectiveness of infliximab maintenance treatment at
he licensed dose of 5 mg/kg in comparison with palliative
are without infliximab and other TNF- inhibitors for the
reatment of patients with active and progressive psoriatic
rthritis who have had treatment failure with at least two
MARDs. A separate analysis was also performed for the
ubgroup of patients with psoriatic arthritis who demon-
trated a significant psoriatic component at baseline, de-
ned as psoriasis affecting body surface area (BSA) of at
east 3%. wethods
atients and interventions
he economic analysis focused on patients with active and
rogressive psoriatic arthritis, among whom two-thirds had
ignificant psoriasis at baseline, with the patient population
eing based on that studied in infliximab clinical trials (IM-
ACT and IMPACT2) [7,8]. The effect of a TNF- inhibitor on
he rheumatic component of the disease across all patients
as estimated by means of the Health Assessment Ques-
ionnaire (HAQ) score. In the subgroup with significant pso-
iasis at baseline, the effect on the psoriatic component of
he disease was also estimated with psoriasis area severity
ndex (PASI). For the a third of the patients with psoriatic
rthritis who showed no clinically significant psoriasis (af-
ected BSA 3%), only the impact on the rheumatic compo-
ent was modeled. For the cohort of patients with psoriatic
rthritis, a mean HAQ score of 1.14 (range 0–3) was assumed
t baseline. For the two-thirds with significant psoriasis at
aseline, a mean PASI score of 11 (range 0–32) was assumed.
atients entered the model at the age of 45 years, and 50%
ere men.
The analysis compared four treatment alternatives.
hese included maintenance treatment with a TNF- inhib-
tor (infliximab, adalimumab, or etanercept) followed by a
equence of nonbiologic DMARDs or palliative care com-
rising only nonbiologic DMARDs. The analysis was con-
ucted with a time horizon of 40 years, and half-cycle cor-
ection was applied.
odel overview
hemodel structure in terms of the cohort flow is displayed in
igure 1 and is based on the model previously developed by
ravo Vergel et al. [9]. The main distinction between our
odel and that used previously is the explicit consideration of
he psoriatic component of the condition. The model can be
ummarized as having a first cycle starting at 0 and running to
2 weeks, a second cycle of 13 to 24 weeks, and annual cycles
hereafter. In contrast to the Bravo Vergel et al. model [9], a
econd cycle of 12 weeks stretching from week 13 to week 24
as included on the basis of trial analysis of infliximab trials
uggesting that improvements in the rheumatic and psoriatic
omponents of the disease continue beyond the initial 12
eeks. At the end of the first cycle, all patients were assessed
or their Psoriatic Arthritis Response Criteria (PsARC) re-
ponse. Those who had response to treatment continuedwith
he current treatment, whereas those without response had
he treatment withdrawn and moved on to palliative care.
fficacy estimates and transitions
he efficacy estimates were derived with the incremental
reatment effects for the comparative treatments (infliximab,
tanercept, and adalimumab). Because no head-to-head trials
etween TNF- inhibitors were available, evidence synthesis
as undertaken with Bayesian indirect comparison tech-
n
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17V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 - 2 3iques. The analysiswas conductedwithWinbugs/OpenBUGS
ersion 3.0.3, and the code is available in Appendix A found at:
0.1016/j.jval.2010.10.016. Noninformative priors were used
or all parameters, and sensitivity to the choice of priors was
ssessed by rerunning the analysis for different priors. The
esults did not vary substantially (i.e., the posteriors are dom-
nated by the data and not by the choice of prior). Sampling
onvergence was verified with the Brooks-Gelman-Rubin dia-
ram. The results were then used in the economic model to
stimate the cost-effectiveness of TNF- inhibitor treatments
n patients with psoriatic arthritis.
The network of evidence used is displayed in Figure 2, and
he data used in the indirect comparison are displayed in Ap-
endix B found at: 10.1016/j.jval.2010.10.016. The outcomes of
nterest were PsARC response, the effect on HAQ score and, in
he subgroup of patients with BSA at least 3% at baseline, the
ffect on PASI score. Clinical trial data from the last data
oints before the early escapewere used. The PsARC response
as modeled with the probability of a PsARC response with
lacebo and a treatment-related increment, which was as-
umed to be on the log-odds scale. Similarly, the change in
AQ score from baseline was modeled conditional on PsARC
esponse with placebo plus a treatment-related increment,
ig. 1 – Economic model structure. Char, characteristics; PsA
at Hist, natural history; t0, t1, t2, model cycles.
Study Placebo
Antoni 2005a[7] PsARC/PASI P
Antoni 2005b[8] PsARC/HAQ/PASI PsA
Mease 2000[20] PsARC/PASI
Mease 2004[21] PsARC/PASI
Mease 2005[20] PsARC/HAQ/PASI
Genovese 2007[23] PsARC/HAQ
Bravo Vergel 2006[9] HAQFig. 2 – Network of evidence used for Peparately among those with and without PsARC response.
or the subgroup of patients with significant psoriasis, the
hange in PASI scorewas alsomodeled as placebo plus a treat-
ent-related increment but without conditioning on PsARC
esponse. The PASI score changewas assumed to be unrelated
o PsARC response on the basis of the analysis of patient level
ata from IMPACT and IMPACT 2.
Beyond the first cycle, the model assumed continued HAQ
core reduction for patients responding to treatment for the
rst three cycles (12, 12, and 52 weeks). The assumption was
ased on the analysis of IMPACT and IMPACT 2, which esti-
ated the incremental HAQ score reductions among those
ith treatment responses to be 0.0628 and 0.0313 relative
o those with placebo responses in the second and third cy-
les, respectively. This HAQ score reductionwas estimated for
nfliximab. In the absence of any data on differential HAQ
core reduction among TNF- inhibitors, identical estimates
ere used for all treatments. For patients withdrawing from
reatment, rebound was assumed to occur within one cycle
nd estimated to be equal to gain, with natural history disease
rogression thereafter (Curve A-C-D-E-F). This assumption
as further explored in one-way sensitivity analysis, wherein
he rebound was assumed to be equal to the natural history
, response at week 12 according to PsARC; Pall, palliation;
ab Etanercept Adalimumab
/PASI
Q/PASI
PsARC/PASI
PsARC/PASI
PsARC/HAQ/PASI
PsARC/HAQ
HAQRC12Inflixim
sARC
RC/HA
HAQsARC, HAQ, and PASI responses.
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18 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 - 2 3isease progression with only palliative care (Curve A-B).
hese scenarios are depicted in Figure 3. The natural history
isease progression for HAQ score was derived from the Leeds
ESPAR study and was estimated to be 0.0719 per year [9]. In
he case of PASI score, the model assumed a flat PASI score
enefit beyond the initial decrement in the first cycle. This
ssumption was based on expert opinion, which also sug-
ested no natural history PASI score progression for patients
ot treated with TNF- inhibitor therapy. For patients with
ost response, the PASI score was assumed to rebound back to
aseline within a cycle of withdrawal and remain at that value.
Beyond the first cycle, all patients had an annual probability
f 11.14%, identical for all treatment alternatives, of withdrawal
rom treatment and moving onto palliative care [10]. The Ge-
orek et al. study [11] estimated thewithdrawal rates for etaner-
ept and infliximab for a 17-month period in which 43 patients
ut of 279 withdrew from TNF- inhibitor treatment. The prob-
bility of death was estimated for the general population and
djusted with psoriatic arthritis mortality multipliers of 1.60 for
emale patients and 1.66 for male patients [11].
osts
erspective
he perspective adopted for costs was that of the National
ealth Service in England andWales. The reference year used
or costs was 2008, with all costs except the drug costs being
nflated according to Personal Social Services Research Unit
nflation indices. Productivity losses, although significant,
ere omitted because of this choice of perspective.
rug administration and monitoring costs
he total cost of infliximab treatment was broken down into
ts acquisition cost (£419.62 per 100-mg vial) taken from the
Fig. 3 – HAQ score redu
Table 1 – Drug costs.
1st cycle
Infliximab (60–80 kg) £3776.58 to £5035.44
Etanercept £2145.12
Adalimumab £2145.00ritish National Formulary and administration cost. Be-
ause dosing for infliximab is weight dependent, the base
ase was presented for a range of 60 to 80 kg per patient
eight. Patients with body weights within this range were
ssumed to vial optimize, thus saving significant drug costs.
his assumption was based on a survey of rheumatology
enters in the United Kingdom suggesting that a majority of
ll rheumatology patients receive vial optimized infliximab.
reatment costs for other TNF- inhibitors were also taken
rom the British National Formulary. The resultant drug
osts for the first and subsequent cycles are displayed in
able 1.
For the administration costs, it was assumed that during
he first cycle the subcutaneous formulations would require
n initial consultant outpatient visit followed by two separate
-hour nursing staff visits to educate the patient in self-ad-
inistered injections, together costing £394.09 per patient.
he infusion cost used for infliximab was £124 per infusion
ccording to a previous appraisal [12]. On an ongoing basis,
he subcutaneous TNF- inhibitors were assumed to require
wo outpatient visits coupled with 1 hour of staff nurse time
or monitoring in each subsequent year, together costing
309.06 per patient. The corresponding resource use for in-
iximab was a single outpatient visit costing £135.71 per
atient per year. Because of the hospital-based dosing, it
as assumed that infliximab monitoring costs would be in-
urred during infusion administration, and thus no addi-
ional costs were applied. All TNF- inhibitors were as-
umed to be accompanied by annual laboratory tests
osting £82.65 per patient.
ngoing costs
he ongoing costs were estimated as a function of HAQ score
or the third of patients with no psoriatic component and as a
n and rebound effect.
2nd cycle Annual thereafter
£2517.72 to £3356.96 £8182.59 to £10910.12
£2145.12 £9295.52ctio£2145.00 £9295.00
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19V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 - 2 3unction of HAQ and PASI scores for the remaining two-thirds
f patients. The cost per HAQ score change regression derived
rom a study by Kobelt et al. [13] estimated a resource use cost
f £401 (SE £259) per point increase in HAQ score per year with
constant of £1325 (SE £466). In line with the Bravo Vergel et
l. model [9], patients continuing treatment were assumed to
ncur 85% of these costs, whereas those withdrawing from
reatment and moving on to palliative care were assumed to
ncur 100% of these costs [9]. The cost as a function of PASI
core was derived from a survey of 20 dermatologists. The
espondents were selected by stratified sampling according to
eography, size of the practice, clinic setup (coclinic with
heumatology vs. separate), and previous experience with
NF- inhibitors. A majority of the questions in the survey
ere closed ended and asked the respondents to estimate
he resource use for a range of PASI scores (5, 5–9, 10–19,
0–29, 29). The responses were then used to estimate the
esource use costs, including the dermatology inpatient,
onsultant-led outpatient, nurse-led outpatient, and photo-
herapy costs according to PASI scores. On the basis of the
esults, an additional cost of £167 per PASI score point in-
rease was applied for the subgroup of patients with signif-
cant psoriasis at baseline.
utcomes
he primary outcome was quality-adjusted life years
QALYs), estimated as a function of both the HAQ and the
ASI scores. The literature search did not identify any util-
ties for patients with psoriatic arthritis estimated directly
ith EQ-5D or SF-6D. Therefore two indirect methods pub-
ished in the literature with SF-36 (SF-12) mapping to EQ-5D
nd then on to utilities [14] and SF-36 (SF-6D) mapping di-
ectly to utilities [15] were used. The current National Insti-
ute for Health and Clinical Excellence (NICE) Methods
uide explicitly prefers EQ-5D, and we therefore selected
he Gray algorithm in the base case, with the Brazier algo-
ithm being explored in the sensitivity analysis [16]. The
egression models based on these algorithms are displayed
n Table 2.
ost-effectiveness analyses
he results of the cost-effectiveness analysis are reported
ere in the form of incremental cost per QALY gained. Costs
nd outcomes were calculated separately for each treatment
Table 2 – Utility estimation algorithms.
Brazier algorithm
Covariate Mean
Intercept 0.6373442 0.
sHAQ 0.0976821 0.
sPASI 0.0253398 0.
sHAQ2 0.0111282 0.
sPASI2 0.0040523 0.sHAQ  (HAQ  0.85730)/0.66497. sPASI  (PASI  5.13489)/7.30676. SE, stalternative and were discounted at 3.5% per annum, in accor-
ance with the NICE guidelines [16]. In the base case, the cost-
ffectiveness was estimated for all patients with psoriatic ar-
hritis. A separate subgroup analysis was conducted for
atients with significant psoriasis at baseline (BSA3%). Mul-
iple one-way sensitivity analyses were conducted, varying
he parameters such as baseline HAQ and PASI scores, time
orizon, HAQ score reduction beyond first cycle, withdrawal
ates, natural history HAQ score progression, and utility esti-
ates to assess the structural and parametric uncertainty
round the model results. The uncertainty surrounding im-
ortant variables was further explored with probabilistic sen-
itivity analyses with 5000 simulations. In the probabilistic
ensitivity analyses, the PsARC response, the HAQ and PASI
core changes conditional on PsARC response, thewithdrawal
ates, the psoriatic arthritismortalitymultipliers, and the util-
ties were modeled with  distributions. The natural history
isease progression and cost as a function of HAQ or PASI
core were implementedwith a normal distribution subject to
non-negative value.
esults
ost-effectiveness analyses
he results of the network meta-analysis used in the model
re displayed in Table 3. The results showed that all TNF-
nhibitors were significantly superior to palliative care for
sARC response in all patients and PASI score improvement
mong patients with significant psoriasis. In addition, in-
iximab and etanercept were superior to palliative care for
AQ score improvement. Among the TNF- inhibitors, in-
iximab and etanercept were broadly similar, with inflix-
mab being numerically superior with regard to PsARC re-
ponse and PASI score improvement and etanercept being
umerically better with regard to HAQ score improvement.
oth infliximab and etanercept were superior to adali-
umab with regard to PsARC response but comparable with
egard to other outcomes.
The analysis estimated that less than 50% of patients were
eceiving TNF- inhibitor treatment by the end of the fourth
ear, and less than 1% were receiving treatment by the end of
odel time horizon. The costs and benefits associated with
ach treatment and the resulting incremental analyses for all
atients with psoriatic arthritis and those with significant
Gray algorithm
Mean SE
71 0.6442260 0.0115177
40 0.1610008 0.0087963
15 0.0375632 0.0132345
56 0.0050072 0.0067073
51 0.0051515 0.0030365SE
00445
00340
00512
00259
00117ndard error of the mean.
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20 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 - 2 3soriasis are displayed in Table 4. The results demonstrated
hat for a typical patient with psoriatic arthritis weighing as
uch as 100 kg, all three TNF- inhibitors were cost-effective
elative to palliative care. The incremental cost-effectiveness
atios (ICERs) for etanercept, adalimumab, and infliximab rel-
tive to palliative care were £17,327; £19,246; and £16,942 to
23,022, respectively, across all patients with psoriatic arthri-
is and £16,613; £18,170; and £15,788 to £21,736, respectively,
n the subgroup of patients with significant psoriasis at base-
ine.
ensitivity analyses
he results of one-way sensitivity analysis are displayed in
able 5. Results were sensitive to change in structural as-
umptions such as utility estimates and HAQ score rebound
fter TNF- inhibitor withdrawal, as well as parametric mod-
fications such as halving the rate of natural HAQ score pro-
ression, resulting in ICERs greater than £30,000/QALY. The
ffects of changes in other parameters, such as discount rate
0–6%), sex, and model time horizon, were less significant.
he results of the probabilistic sensitivity analyses suggest
nfliximab to be cost-effective with a willingness to pay that
ould be as low as £12,000 for typical patients with psoriatic
rthritis, as displayed in Figures 4A and 4B.
Table 3 – Results of the network meta-analysis.
Outcome Placebo (mean  SE, 95% CI) Infliximab (mean
PsARC response 0.261  0.021 (0.220, 0.304) 0.769  0.036 (0.
HAQ score change from
baseline, PsARC
responders
0.268  0.061 (0.383, 0.146) 0.636  0.073 (
HAQ score change from
baseline, PsARC
nonresponse
0.016  0.031 (0.048, 0.075) 0.167  0.059 (
PASI score change from
baseline, BSA 3%
subgroup
0.752  0.515 (0.196, 1.734) 6.585  0.924 (
SE, standard error of the mean; CI, confidence interval.
Table 4 – Base case results for patient weight of 60 to
80 kg.
Total
QALYs
Total costs ICER vs.
palliative care
All patients
Palliative care 6.10 £64,704 —
Adalimumab 7.89 £99,278 £19,246
Etanercept 8.62 £108,481 £17,327
Infliximab 8.65 £107,954–£123,475 £16,942–£23,022
Psoriasis patients
Palliative care 5.79 £76,402 —
Adalimumab 7.63 £109,682 £18,170
Etanercept 8.35 £118,925 £16,613O
Infliximab 8.40 £117,606–£133,128 £15,788–£21,736iscussion
nfliximab is an efficacious treatment alternative for patients
ith active and progressive psoriatic arthritis [7,8]. The objec-
ive of this analysis was to assess the cost-effectiveness of
nfliximab treatment at the licensed dose of 5 mg/kg in pa-
ients with psoriatic arthritis. Three studies in the literature
ave estimated the cost-effectiveness of TNF- inhibitors in
soriatic arthritis [9,17,18]. All three studies adopted models
eported in the literature for rheumatoid arthritis and used
heumatoid arthritis data for key parameters, such as the re-
ationship between HAQ score and costs. None of the studies,
owever, captured the impact of TNF- inhibitors in improv-
ng the symptoms of psoriasis, thus excluding the benefit aris-
ng from treating psoriasis. The study by Olivieri et al. [18]
aptured the benefit of TNF- inhibitors for a period of 6
onths after treatment initiation, whereas the other two
tudies used models that extended beyond the trial period
nd out to 10 years. For a chronic condition such as psoriatic
rthritis, capturing the benefits over the lifetime of the pa-
ient may be more appropriate. The study by Bravo Vergel et
l. [9] compared infliximab and etanercept with each other
nd with standard care, whereas the other two studies only
ompared the TNF- inhibitor with standard care. Also,
one of the studies included adalimumab as a treatment
lternative. We attempted to address these limitations of
he previous works in our analyses. We selected the model
tructure developed by Bravo Vergel et al. [9] because it was
eemed to be the most appropriate and robust analysis in a
revious NICE appraisal [19]. Our results indicated the cost-
ffectiveness of TNF- inhibitors to be in the range of
17,327 to £23,022 per QALY, which is lower than values
eported in the literature [9,17,18]. This may be attributable
o a variety of factors, including accounting for the TNF-
nhibitor benefit in psoriasis and lifetime estimates of costs
nd benefits.
TNF- inhibitors when compared with each other
howed little difference in effectiveness. Adalimumab was
ignificantly worse with regard to the PsARC response but
nly numerically inferior with respect to HAQ and PASI
core changes relative to the other two TNF- inhibitors.
95% CI) Etanercept (mean  SE, 95% CI) Adalimumab (mean  SE, 95% CI)
835) 0.748  0.041 (0.663, 0.823) 0.586  0.038 (0.509, 0.658)
0.502) 0.705  0.077 (0.853, 0,552) 0.458  0.128 (0.705, 0.203)
0.056) 0.212  0.071 (0.351, 0.073) 0.184  0.133 (0.446, 0.078)
4.839) 4.070  0.826 (5.692, 2.551) 5.358  3.924 (14.09, 2.541) SE,
695, 0.
0.790,
0.285,
8.345,ur network meta-analysis used patient-level data from in-
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21V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 - 2 3iximab clinical trials and used published meta-analysis
esults for etanercept drawn from patient-level information
10,20,21]. Such information was not available for adali-
umab, however, and we used published trial results
Table 5 – Results of one-way sensitivity analyses (patients
Parameter change Et
Reducing baseline HAQ score from 1.14 to 0.90 £17,
No HAQ score change beyond first cycle £18,
Reducing baseline PASI score from 11.0 to 9.0 £17,
Applying 20-year time horizon £21,
Rebound equal to natural history £29,
Halving annual withdrawal from TNF- inhibitor treatment
from 11.14% to 5.6%
£18,
Halving rate of HAQ score progression under natural
history from 0.072 to 0.036
£24,
Applying Brazier algorithm for quality of life £37,
ig. 4 – (A) Cost-effectiveness acceptability curves and fronti
nd frontier for 80-kg patient.22,23]. These results may have contributed to adalimumab
eing significantly worse with regard to PsARC response.
ecause the TNF- inhibitors were similar with regard to
he efficacy results, we treated them as a class and did not
psoriasis).
ICERs vs. palliative care
cept Adalimumab Infliximab 60–80 kg
16,464) £18,984 (£17,927) £16,774–£22,797 (£15,634–£21,527)
17,903) £20,932 (£19,736) £18,304–£24,832 (£17,035–£23,410)
16,558) £19,184 (£18,083) £16,882–£22,940 (£15,705–£21,621)
20,309) £24,148 (£22,710) £20,874–£28,247 (£19,381–£26,560)
27,944) £35,968 (£33,487) £28,989–£39,029 (£26,682–£36,365)
17,340) £20,254 (£19,095) £17,406–£23,658 (£16,183–£22,292)
23,399) £28,619 (£26,827) £24,112–£32,552 (£22,318–£30,508)
35,603) £44,262 (£41,372) £36,870–£50,095 (£34,026–£46,843)
r 60-kg patient. (B) Cost-effectiveness acceptability curveswith
aner
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22 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 5 - 2 3resent ICERs comparing them. Similar efficacy resulting in
mall incremental benefit may produce a wide range of IC-
Rs, from being dominant to very high, especially when
omparing infliximab and etanercept. The uncertainty in-
reases further particularly depending on the assumptions
round rebound effect and the quality of life algorithm. This
ack of consensus regarding methods and assumptions
ranslates into considerable uncertainty around cost-effec-
iveness results. Further research is needed to address some
f these uncertainties. In light of this, the treatment costs,
ncluding the cost of drug acquisition, are likely to play a
ignificant role in the choice of TNF- inhibitor. It is impor-
ant to note that our interpretation of results is in direct
ontradiction to the current NICE guidance, which recom-
ends adalimumab and etanercept ahead of infliximab for
reatment of psoriatic arthritis [19,24]. It is also important,
owever, to consider the context in which NICE made that
ecision. The Bravo Vergel et al. [9] analysis that informed
he NICE appraisal committee did not incorporate the pso-
iatic benefit of TNF- inhibitors. As a result, the ICERs for
tanercept and adalimumab were below the acceptability
hreshold of £30,000/QALY, whereas the ICER for infliximab
as above the threshold. This may have influenced NICE to
ecommend etanercept and adalimumab ahead of inflix-
mab. Our analysis suggests that all the TNF- inhibitors
ave ICERs well below the acceptability threshold and
herefore should be considered as appropriate treatment
lternatives, even within the NICE constraints. This is likely
o be reflected in the NICE’s decision on an ongoing ap-
raisal of TNF- inhibitors in psoriatic arthritis [25,26].
The sequence of treatments modeled is an important con-
ideration in psoriatic arthritis. We did not include sequential
reatment with a second TNF- inhibitor for patients with pri-
ary nonresponse or thosewithdrawing from treatment. This
as primarily because of unavailability of psoriatic arthritis–
pecific data on sequential use. Our model was based on that
sed by Bravo Vergel et al. [9], and we made the necessary
tructural and parametric changes to incorporate new evi-
ence. The important modifications included adding in a sec-
nd cycle of 12 weeks stretching fromweek 13 to week 24 and
he additional assumptions regarding continued HAQ score
eduction up to the third cycle. These modifications were
ased on the clinical trial analysis of infliximab, which sug-
ested continued improvements in rheumatoid and psoriatic
omponents among those with treatment response. In the ab-
ence of any similar evidence regarding other TNF- inhibi-
ors, however, the comparative ICERs should be interpreted
ith caution. We also excluded the adverse events from our
nalysis. The clinical trials have demonstrated that the ad-
erse events associated with TNF- inhibitors are infrequent,
inor, and not significantly different from those associated
ith palliative care. We therefore would not anticipate ad-
erse events to have a significant impact on the costs or
ALYs and thus on the final results. On the contrary, the util-
ty estimation method significantly affects the ICERs. We se-
ected EQ-5D in the base case because it is recommended by
ICE and has been used in previous analyses. We believe that
Q-5D is a more appropriate scale in psoriatic arthritis be-
ause of its domains (mobility, self-care, usual activities, and tain), which capture highly relevant information on parame-
ers affecting a patient with psoriatic arthritis. The use of util-
ties derived from SF-36, however, significantly increases the
CERs.
The rebound assumption after treatment withdrawal is
lso an important one. We assumed rebound equal to gain in
ur base case analysis and explored the surrounding uncer-
ainty in sensitivity analysis. The ICERs increased but were
till within the acceptable range for patients receiving etaner-
ept and a proportion of those receiving infliximab. With no
onclusive evidence of rebound effect in the literature, how-
ver, it is difficult to ascertain the true impact of this assump-
ion on the resultant ICERs. Similarly, in absence of any data in
iterature regarding PASI score natural progression and PASI
core rebound after loss of response, we assumed PASI score
ould remain constant as long as the patient had a response
nd would revert back to baseline after loss of response. This
s in accordance with a recent NICE appraisal [25]. Because of
he lack of any available data, it is impossible to determine
hether this assumption is optimistic or conservative and
ow much the PASI score should be varied with time to esti-
ate the underlying uncertainty. Any such sensitivity would
ave contributed equally to all TNF- inhibitors, however, and
ould have minimal impact on their positioning relative to
alliative care. We therefore did not explore the uncertainty
round this assumption in our sensitivity analysis. Our results
re also sensitive to the number of infliximab vials used per
nfusion and the assumption of vial optimization. We pro-
ided a range of results derived for a mean patient weight in
he range of 60 to 80 kg. Despite the uncertainty outlined here,
nfliximab moves further away from subcutaneous TNF- in-
ibitors for patients with psoriatic arthritis weighing less than
0 kg ormore than 80 kg. These are important parameters that
ay influence the treatment choice among TNF- inhibitors.
onclusion
nfliximab isaneffectiveandwell-tolerated therapy for theman-
gement of patientswith active and progressive psoriatic arthri-
is andprovides significant clinical benefitwith respect to pallia-
ive care. Economic analyses demonstrate that the incremental
osts associated with achieving these benefits are reasonable
nd that infliximabmay represent a cost-effective treatment op-
ion well within the NICE threshold relative to palliative care
ithout biologic DMARDs. Because of equivalent outcomeswith
ther TNF- inhibitors, the position of infliximab in the treat-
ent pathway within a resource-constrained health system is
ikely to be governed by treatment costs.
upplementary Data
upplementary data associatedwith this article can be found, in
he online version, at 10.1016/j.jval.2010.10.016.
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